Herpes Zoster following SARS‐CoV‐2 vaccination – a series of four cases

Alpalhão, Miguel; Filipe, Paulo

doi:10.1111/jdv.17555

Cited by 31 publications

(27 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 24 patients from seven articles mentioned a prior history of HZ or varicella and 16 patients had a prior history of these (Alpalhão & Filipe, 2021 ; Channa et al, 2021 ; Furer, Eviatar, et al, 2021 ; Lee et al, 2021 ; Psichogiou et al, 2021 ; Tessas & Kluger, 2021 ; van Dam et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

A narrative review and clinical anatomy of herpes zoster infection following COVID‐19 vaccination

Iwanaga

Fukuoka

et al. 2021

Clinical Anatomy

View full text Add to dashboard Cite

Introduction: In this review, cases of herpes zoster (HZ) infection following receipt of COVID-19 vaccines will be analyzed. We also present two cases of oral HZ following the COVID-19 vaccine and discuss this clinical anatomy.Materials and Methods: A database search using PubMed was conducted in August 2021 and 20 articles were found to be eligible for review. Patient data and vaccine information were analyzed. In addition, two cases of oral HZ infection following the receipt of COVID-19 vaccines are presented.Results: A total of 399 cases were identified. The affected dermatomes mimicked the regular distribution of HZ. For the dermatomes of the face, the various reports used different ways to describe the areas involved; CNV, CNV1, CNV2, CNV3, lower jaw, forehead, and under the eyebrow (CNV, 2 cases; CNV1, 4 cases; CNV2, 3 cases; and CNV3, 3 cases). Some patients who had a history of varicella zoster virus vaccination had HZ following the COVID-19 vaccination. Two patients with oral HZ following vaccination were found to have involvement of the greater palatine nerve.Conclusions: Vaccine-related HZ cases have been reported worldwide. Although many studies with a larger number of cases are ongoing, detailed information can be obtained from case reviews as reported herein.

show abstract

Section: Resultsmentioning

confidence: 99%

A narrative review and clinical anatomy of herpes zoster infection following COVID‐19 vaccination

Iwanaga

Fukuoka

et al. 2021

Clinical Anatomy

View full text Add to dashboard Cite

show abstract

“…Cases were reported worldwide including USA, 10 , 11 Lebanon, 12 Turkey, 13 , 14 , 15 Greece, 16 Italy, 17 India, 18 Israel, 19 Finland, 20 Taiwan, 21 Spain, 22 and Portugal. 23 There were cases with known risk factors for herpes zoster, which included age more than 50 years ( n = 36), immunological disorders ( n = 10), chronic disease ( n = 25), metabolic disorder ( n = 13), malignancy ( n = 4), and psychiatric disorder ( n = 2). Table 1 shows the details of cases.…”

Section: Resultsmentioning

confidence: 99%

“… 25 , 30 , 31 Of 54 herpes zoster reported cases, 52 (96.29%) of the patients developed it at the defined higher risk timeframe (1–21 days after the initial dose). 23 As a result, the AEAV may be categorized as "compatible with," and a "likely" causal relationship based on the World Health Organization Working Group can be presented, indicating the existence of a temporal link and a credible physiological mechanism. 25 , 30 , 31 , 32…”

Section: Discussionmentioning

confidence: 99%

Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

Desai

Sharma

Shah³

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…The 3 patients of our series had a medical history of hypertension and dyslipidaemia, similar to previous reports. 1 , 2 , 4–11 , 13 These associated conditions may increase the risk of VZV reactivation. None of the patients was previously immunosupressed.…”

Section: Discussionmentioning

confidence: 99%

“…As seen in Patients #1 and #3, previous reports described 10 patients who performed the second dose of the vaccine against COVID-19 without signs of VZV reactivation. 3 , 8 , 10 , 13 , 18 Thus, shingles after the first dose of the vaccine against COVID-19 should not discourage the complete vaccination schedule.…”

Section: Discussionmentioning

confidence: 99%

Varicella zoster virus reactivation following COVID-19 vaccination: a report of 3 cases

Saraiva¹,

Vieira²,

Marinho³

et al. 2022

Family Practice

View full text Add to dashboard Cite

Background The advent of vaccination against COVID-19 brought great expectations for the control of the pandemic. As novel vaccines, much of the associated side effects were unknown. Currently, an increasing number of reports from side effects of COVID-19 vaccines have been published, namely on cutaneous reactions. These are of utmost importance to increase our knowledge about possible undesirable effects and its prevention. Methods We describe a series of 3 cases who presented with varicella zoster virus (VZV) reactivation following the first dose of 3 different COVID-19 vaccines. Results Three patients sought their Family Doctor after developing typical lesions of VZV reactivation, following a period of 3–13 days after COVID-19 vaccination. None was under immunosuppressive therapy. The 3 patients recovered in a few weeks and the subsequent doses of the vaccines were administered, without recurrence of the symptoms. Conclusions These cases highlight the possibility of VZV reactivation after the first dose of COVID-19 vaccines. Family Doctors should be aware of this event and play an important role informing and reassuring local communities for this possible vaccine reaction.

show abstract

Herpes Zoster following SARS‐CoV‐2 vaccination – a series of four cases

Cited by 31 publications

References 7 publications

A narrative review and clinical anatomy of herpes zoster infection following COVID‐19 vaccination

A narrative review and clinical anatomy of herpes zoster infection following COVID‐19 vaccination

Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

Varicella zoster virus reactivation following COVID-19 vaccination: a report of 3 cases

Contact Info

Product

Resources

About